HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms - Wikidata - awgldk - TriplyDB

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

http://www.wikidata.org/entity/Q36877910

about

Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery A multi-system approach assessing the interaction of anticonvulsants with P-gp Single Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive Individuals Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein.Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.Pharmacogenomics of antimicrobial agents.Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers.Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability.Pharmacogenetics in the brazilian population.Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice.Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.Individualization of antiretroviral therapy.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.Clinical pharmacokinetics of antiretroviral drugs in older persons.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2 Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex

P2860

Q24564462-864AEB9E-306F-44BD-8707-7BA4211F2312 Q26853274-8DCFDBA0-D745-4B27-8957-504D97DE47A3 Q27001267-8ABEA932-8DE3-4115-8DC2-AF15CDA36F8D Q28081272-1E220613-BB5C-4763-B107-69B4A3A562A6 Q28533527-DD9F38B6-6AAA-41FF-8AAE-8815E809F202 Q28554250-42777DE9-7C33-4CDC-819B-FCDC9EC1C9BC Q33760652-E4FB34A9-C3B2-4B4B-8142-1AFBD19B484F Q34057466-584D0685-C48E-4599-AC15-6A12A0232B3E Q34309475-1307941C-44A3-429A-9DDD-C81E0D6AC55D Q34385711-BD4B6FD3-EB8C-41B6-AF28-169F9E4943D0 Q34529127-D832B8BB-99B1-4B9C-83B0-FFF8C08A0146 Q34534986-D9379963-2BA6-4B48-B6E6-DBB6C5EE2F6A Q34710705-F43E68B7-8923-472E-B1F1-8FE1B6E77E15 Q34758192-1676C055-845D-4CD7-A954-A6E95E73B106 Q34763589-EB30AF69-D341-4C84-A9B1-03AB2437221F Q34977413-CFC102CD-3D66-431E-B0A4-FA33990ADA5F Q35080119-CCEFF4D7-6AD9-4566-9D58-C09CE3A1B53E Q35088420-6F4CC3FA-9E4E-4A07-B3EC-159899852507 Q35113316-5245D3A0-ED2F-4E7B-80D2-5B9906D434BD Q35146960-6DB59ED7-4D97-4C8A-80C6-FA5E06FDF172 Q35155213-5F8BDB74-175A-4203-8F67-7F82BA2EB18E Q35264245-C564AA65-9BA6-48C0-8B7F-7213547EAAE3 Q35488671-FABC5CDF-B8B8-402D-885A-F8C7B08889DC Q35595787-B3C462EC-7548-4AC0-BD7B-8ACAF72F4ECE Q35878413-5C3867E3-B652-421D-98BD-BD43172C9D98 Q35960706-671BAE39-D191-4B07-895B-5838F6CF0D6B Q36000004-42675AEF-AE36-40BD-80EA-489B21F3CF40 Q36238198-D5C8604E-A17F-49F5-B51E-E24D6E29CB16 Q36359372-F7B4E76E-7227-487E-8274-40B34CFEA784 Q36439164-D93AE066-F241-4FD2-9E78-3FA32D21E3CE Q36441423-986D591C-5373-49FB-963E-96928ECF22E2 Q36599597-B746CB09-B718-48A5-9943-D27751C4ACC5 Q36701911-EE2E8C39-F533-4260-B6F3-E6BB4F9DC53E Q36763108-9FD8A864-517A-483F-84F0-2177C36DF879 Q36905884-70E2D8F1-0805-47A7-B328-C2B1DA3BE26A Q37113947-91281714-5DEF-4B99-B6B8-702CE4A77F46 Q37207831-DD0B59A6-1C6E-4C00-B355-1EE780A7066D Q37232200-14F79FDC-DCAC-4DA0-97E7-4041654D5C4C Q37263486-0E330280-0D9C-4068-B0ED-AAC00E454878 Q37422685-BAA86CF4-3231-4750-ABAA-D41DD2D83FF7

P2860

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

http://www.wikidata.org/entity/Q36877910

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

HIV protease inhibitors are su ...... enced by SLCO1B1 polymorphisms

@en

type

label

HIV protease inhibitors are su ...... enced by SLCO1B1 polymorphisms

@en

prefLabel

HIV protease inhibitors are su ...... enced by SLCO1B1 polymorphisms

@en

P1433

Q36877910-A092B1D1-3AA2-4DF7-ADDE-737AAA1CA7B1

P1476

Q36877910-514A6C75-06E2-4176-9EDA-DD2F22EFD8E0

P2093

Q36877910-046DE9FA-45C6-4EB1-9D0C-965DF623F8BE

Q36877910-13F5E1E5-F41C-4546-B3F5-5CC350C39018

Q36877910-4047F7A9-222F-42BE-8B0C-D6A7F3E986B8

Q36877910-438671AA-F914-4073-A7DD-D0F0EA2D3974

Q36877910-48E4C54C-E717-4FFA-8DC8-3326A19D78AD

Q36877910-5436CE44-BD1B-456D-9DDC-B3F8D492D2ED

Q36877910-8B9850D3-E5E3-45C7-83BC-85730BF2B0FE

Q36877910-B2303EA7-0D05-450A-8C7E-174B86CA1D95

Q36877910-C7F3A3DF-FAB8-499A-8FEE-2F3025B3A9D5

Q36877910-CAE14CE3-7828-496E-AE5D-85638C9B39C0

P2860

Q36877910-0225F47A-F15A-449B-BFED-9B91938257C3

Q36877910-09CB99DE-336C-47BD-B1F2-EC2A4A836DCF

Q36877910-0D91A9D0-1427-4F8E-A3E6-7329EAA67B94

Q36877910-100C6C2F-8AAD-4121-9229-2B01BD55A064

Q36877910-10C8E602-1594-46EA-9BA8-674073892E3B

Q36877910-20292746-7EBC-49A0-851C-67F5EA5E7996

Q36877910-22D2A0E1-F7AB-4388-8D63-7C1EE56F92A7

Q36877910-33868B41-0C56-4927-826F-0A2C9122A2D2

Q36877910-357EFF10-FE76-49FD-819B-BA9805B361C9

Q36877910-361228FD-156D-4360-B848-FDCFB3BA1921

P304

Q36877910-3419E178-17E6-4008-82D8-6590BE624465

P31

Q36877910-BDA929CA-2DDC-40B0-8A43-D27C1B94ACF5

P356

Q36877910-A88AA71F-C31F-41D2-8150-65507AAA8E39

P433

Q36877910-0E5775C5-9980-43AA-BD2E-564628FDCD6C

P478

Q36877910-79A210AD-5F43-49FF-85E1-ABFDCB80B3E2

P50

Q36877910-2CD17B18-E14F-4FE2-BA27-49B244AD9515

Q36877910-741CDCA8-480E-4D3E-AC7B-892816D550C6

Q36877910-DC109093-3CF3-43D2-ABDC-26B2EFEED334

P577

Q36877910-AC01CC15-FE6C-4328-B250-962FAF9783FD

P698

Q36877910-98AFB6F6-106D-4C6E-B17A-BE848CEA79B4

P932

Q36877910-39CD0C0C-8C57-4371-BB1C-23EF87127B68

P356

FPC.0B013E328335B02D

P1433

Pharmacogenetics and Genomics

P1476

HIV protease inhibitors are su ...... enced by SLCO1B1 polymorphisms

@en

P2093

Ammara Chaikan

http://www.w3.org/2001/XMLSchema#string

Chloë E James

http://www.w3.org/2001/XMLSchema#string

David J Back

http://www.w3.org/2001/XMLSchema#string

Deirdre Egan

http://www.w3.org/2001/XMLSchema#string

Enrique Salcedo Sora

http://www.w3.org/2001/XMLSchema#string

Pat G Bray

http://www.w3.org/2001/XMLSchema#string

Sara Gibbons

http://www.w3.org/2001/XMLSchema#string

Saye H Khoo

http://www.w3.org/2001/XMLSchema#string

Victoria Shallcross

http://www.w3.org/2001/XMLSchema#string

Wai San Kwan

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer

Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain

Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver

Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver

SLCO1B1 variants and statin-induced myopathy--a genomewide study

P304

112-120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E328335B02D

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Neill J Liptrott

Ruben Hartkoorn

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20051929

http://www.w3.org/2001/XMLSchema#string

P932

4859410

http://www.w3.org/2001/XMLSchema#string